Biocon Biologics Advances in European Market with Positive CHMP Opinions for Biosimilar Denosumab
Biocon Biologics, a subsidiary of Biocon Limited, has received positive opinions from the Committee for Medicinal Products for Human Use (CHMP) for its biosimilar denosumab in Europe. This marks a significant step towards potential approval and market entry in the European Union for the biopharmaceutical company. The biosimilar targets various bone diseases, including osteoporosis and bone metastases. While final approval from the European Medicines Agency is still pending, this development demonstrates Biocon's capabilities in complex biosimilars and positions the company for potential entry into the European biosimilars market.
Biocon, a leading biopharmaceutical company, plans to raise up to ₹45 billion ($540 million) through securities issuance, potentially via QIP or other methods. This move comes as the company experiences significant asset growth but faces increased liabilities and cash flow challenges. Recent financial data shows a 24.44% increase in total assets and a 145.45% rise in current assets, alongside a 238.46% surge in current liabilities. The company's cash flow from operating activities has turned negative, shifting from ₹0.20 billion to -₹0.10 billion year-over-year.